Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

60 results about "Mannose binding" patented technology

Interacting selectively and non-covalently with mannose, a monosaccharide hexose, stereoisomeric with glucose, that occurs naturally only in polymerized forms called mannans. [CHEBI:37684, GOC:jl, ISBN:0192800981]

Mutant proteins, high potency inhibitory antibodies and fimch crystal structure

The present invention provides bacterial immunogenic agents for administration to humans and non-human animals to stimulate an immune response. It particularly relates to the vaccination of mammalian species, especially human patients, with variants of the E. coli FimCH protein that elicit antibodies that have better functional inhibitory activity than antibodies raised against wild type protein. In particular, such variants include mutations that promote a more open confirmation of the FimH protein, particularly in regions involved in mannose binding, to expose regions previously poorly exposed and mutations that abolish a significantly reduce mannose binding. In another aspect, the invention provides antibodies against such proteins and protein complexes that may be used in passive immunization to protect or treat pathogenic bacterial infections. The present invention also provides machine readable media embedded with the three-dimensional atomic structure coordinates of FimCH bound to mannose, and subsets thereof, and methods of using the crystal structure to provide candidate amino acid residues for mutation.
Owner:WASHINGTON UNIV IN SAINT LOUIS +1

Mannose binding lectin and uses thereof

The present inventors have shown that MASP-depleted MBL is able to recruit MASPs from plasma and successfully activate complement cascade. Furthermore, it has been discovered that MBL purified as a complex has limited ability to activate the complement cascade when compared to MASP-depleted MBL. Accordingly, the present invention provides a pharmaceutical composition comprising an isolated non-recombinant mannose binding lectin (MBL) substantially free from activated MBL associated serine proteases (MASPs) together with a pharmaceutically acceptable carrier or diluent. Also provided is a method of treating a subject in need of MBL comprising administering to the subject an effective amount of a pharmaceutical composition of the invention.
Owner:COUNCIL OF THE QUEENSLAND INST OF MEDICAL RES

Fusion Proteins of Mannose Binding Lectins for Treatment of Disease

Fusion proteins having sequences that target specific moieties such as carbohydrates, lipids, and / or proteins that are associated with certain cell types and / or pathogens; and a sequence that induces effector function are provided. The disclosure also provides nucleic acids encoding the fusion proteins, as well as pharmaceutical compositions, methods of use, and methods of treating conditions or diseases such as infectious diseases, cancers, immune related disorders and other ailments, that include the fusions proteins described herein.
Owner:ANAPHORE INC

Complement inhibitory agents as therapeutics in posttraumatic and degenerative arthritis

The present disclosure is directed to methods and compositions for treating osteoarthritis and preventing osteoarthritis, by administering a compound that modulates one or more components in the complement system. In one embodiment, a compound that inhibits a component in the complement system is administered to prevent, delay the progression of, or treat osteoarthritis. In other embodiments, compounds with specific inhibition of a component in a particular pathway in the complement system, such as the alternative, mannose binding lectin, and / or classical pathway, are administered to a subject having osteoarthritis or at risk of developing osteoarthritis.
Owner:UNIV OF COLORADO THE REGENTS OF +2

Polygonatum cyrtonema Hua regeneration system establishment method

The establishing process of Polygonatum cyrtonema Hua regenerating system includes the following steps: inducing the callus of Polygonatum cyrtonema Hua explant; inoculating the callus to differential culture medium and inducing seedling growth; shifting the un-rooted seedling to rooting culture medium to induce rooting; hardening off and transplanting. By means of the process of the present invention, Polygonatum cyrtonema Hua regenerating system may be obtained in 3-4 months and the transplantation survival rate reaches 70-75 %. Compared with medicinal sealwort, the rhizome has similar content of mannose combined hemoglutinin and blood coagulating activity.
Owner:SICHUAN UNIV

Pharmaceutical compositions comprising mannose binding lectin

The present invention relates to pharmaceutical compositions comprising MBL and / or MBL variants. In particular the invention relates to pharmaceutical compositions comprising at least 200 mug / ml protein containing material, wherein mannan binding lectin (MBL) and / or MBL variants constitutes at least 35% (w / w) of the total protein; or to compositions comprising at least 400 mug / ml mannan binding lectin (MBL) and / or MBL variants. In addition the invention relates to pharmaceutical compositions comprising MBL and / or MBL variants and divalent cations. The invention also describes methods of preparing said compositions. The pharmaceutical compositions according to the invention may for example be used in methods of treatment of a number of different clinical conditions including infections. Uses of the compositions for preparation of medicaments for treatment of a clinical condition are also described.
Owner:NATLMMUNE AS (DK) +1

Method of generating an index score for mbl deficiency to predict cardiodiabetes risk

This application relates to methods of predicting susceptibility or likelihood of a clinically-relevant mannose-binding lectin (MBL)-deficient subject to develop a cardiovascular disease and / or cardiodiabetes. The methods include measuring MBL mass or concentration and, optionally, measuring MBL activity, at least one other biomarker and / or genotyping of MBL gene and its promoters; combining the information obtained into a calculated MBL-inclusive index score that involves mathematical transformation; and assigning a risk of cardiadiabetic status and clinical endpoints based on the determination and comparison of the MBL inclusive index to reference values from a population.
Owner:TRUE HEALTH IP LLC

Gene for restoring cadmium contaminated soil and improving cadmium tolerance of plants and application of gene

The invention relates to a gene for improving cadmium tolerance of plants and application of an encoded protein of the gene in restoration of cadmium contaminated soil. The gene for restoring cadmium contaminated soil and improving cadmium tolerance of plants has a sequence shown as SEQ ID No:1 in a sequence table. The gene for improving cadmium tolerance of plants in the invention is transferred into the plants, so that the gene is excessively expressed in the plants, and the plant is cadmium tolerant. When the gene for improving cadmium tolerance of plants is excessively expressed, due to cadmium treatment, the gene can be combined with mannose, and increased expression of related genes such as GSH1, GSH2, PC1, PC2 and the like is promoted, so that the content of GSH and PC is increased. Outside cadmium ions are stored in vacuoles, tolerance to cadmium accumulation is further realized, and the cadmium contaminated soil can be restored to a certain degree.
Owner:HEFEI UNIV OF TECH

Collectins as adjuvants

The present invention provides a vaccine composition comprising a collectin such as mannose binding protein (MBL) and an immunogenic determinant. The invention also describes methods of immunizing individuals with the compositions, and the use of collectins in the preparation of vaccine compositions.
Owner:詹斯·C·詹斯尼厄斯 +1

Gene for improving cadmium accumulation and tolerance of plant, and application thereof

The invention relates to a gene for improving the cadmium accumulation and the tolerance of a plant, and application thereof. The gene for improving the cadmium accumulation and the tolerance of the plant has a sequence as shown in a sequence table SEQ ID No:1, and is applied to repairing cadmium-polluted soil. The gene for improving the cadmium tolerance of the plant is transferred into the plantso as to be overexpressed in the plant, and the plant is cadmium-tolerant. A research result shows that under the condition of cadmium treatment, through overexpressing an MYB4 gene, the gene can bebinded with mannose, and the increased expression of related genes such as GSH1, GSH2, PCS1 and PCS2 is promoted, so that the contents of GSH and PC are increased; an external cadmium ion is stored invacuole, and the cadmium tolerance is expressed.
Owner:HEFEI UNIV OF TECH

Portunus trituberculatus mannose-binding lectin PtMBL gene, encoding protein thereof and application

ActiveCN109797155AEnhanced inhibitory effectAntibacterial agentsAntimycoticsPseudomonas chlororaphis subsp. aureofaciensControl diseases
The invention belongs to the technical field of molecular biology, and particularly discloses a portunus trituberculatus mannose-binding lectin PtMBL gene, an encoding protein thereof and application.The portunus trituberculatus mannose-binding lectin PtMBL gene, the encoding protein and the application have the advantages that PtMBL gene cDNA [complementary DNA (deoxyribonucleic acid)] can be obtained from portunus trituberculatus by means of amplification by the aid of unigene and RACE technologies obtained by means of transcriptome sequencing, and obvious bacterial inhibition, bacterial binding and bacterial agglutination activity of recombinant PtMBL proteins are discovered; obvious inhibition effects can be realized by the recombinant PtMBL proteins for gram-negative bacteria (vibrioalginolyticus and pseudomonas aeruginosa) and gram-positive bacteria (staphylococcus aureus and micrococcus luteus), and the minimum inhibitory concentration is 0.81-1.61 micro-M, 0.81 micro-M, 0.81-1.61 micro-M and 3.22-6.44 micro-M; the recombinant protein PtMBL is obvious in binding activity for the vibrio alginolyticus, the pseudomonas aeruginosa, the staphylococcus aureus, the micrococcus luteus and pichia pastoris; in addition, obvious agglutination effects can be realized by the recombinant protein PtMBL for the vibrio alginolyticus, the pseudomonas aeruginosa, the staphylococcus aureus, the micrococcus luteus and the pichia pastoris in the presence of Ca2+; a foundation can be laid for controlling diseases for the portunus trituberculatus, and the portunus trituberculatus mannose-binding lectin PtMBL gene and the encoding protein have potential application values in the aspects of antibacterial medicine development, bacterial agglutination preparations, novel immunological preparations, feed additive production and the like.
Owner:INST OF OCEANOLOGY - CHINESE ACAD OF SCI

Alocasia odora agglutinin protein gene and its application

A nucleotide (cDNA) sequence of Alocasia agglutinin protein, its coding amino acid (AA) polypeptide sequence, the process for using the gene to transform cotton or other plants, and its application in medicine or other fields are disclosed. Said gene is a member of mannose conjugated agglutinin gene family and is a constitutively expressed gene.
Owner:SOUTH CHINA AGRI UNIV

Fusion proteins of mannose binding lectins for treatment of disease

Fusion proteins having sequences that target specific moieties such as carbohydrates, lipids, and / or proteins that are associated with certain cell types and / or pathogens; and a sequence that induces effector function are provided. The disclosure also provides nucleic acids encoding the fusion proteins, as well as pharmaceutical compositions, methods of use, and methods of treating conditions or diseases such as infectious diseases, cancers, immune related disorders and other ailments, that include the fusions proteins described herein.
Owner:ANAPHORE INC

Immunochromatography kit for fluorescently and quantitatively detecting MBL (mannose-binding lectin)

The invention relates to an immunochromatography kit for fluorescently and quantitatively detecting MBL (mannose-binding lectin). The immunochromatography kit comprises a fluorescence test strip and sample diluent, wherein the fluorescence test strip comprises a bottom plate, a sample pad, a fluorescence binding pad, an enveloped membrane and absorbent paper are sequentially bonded on the upper surface of the bottom plate from one end to the other end, the inner end of the sample pad is lap-jointed with one end of the fluorescence binding pad, the other end of the fluorescence binding pad is lap-jointed with one end of the enveloped membrane, and the other end of the enveloped membrane is lap-jointed with the absorbent paper, wherein the enveloped membrane comprises a detection zone and a quality control zone, the detection zone is enveloped with anti-MBL monoclonal antibody, and the quality control zone is enveloped with goat anti-rabbit IgG; and the fluorescence binding pad contains fluorescently-labeled MBL monoclonal antibody and fluorescently-labeled goat anti-rabbit IgG. The immunochromatography kit for fluorescently and quantitatively detecting MBL has strong specificity and high sensitivity, the detection result acquisition time is short, the operating mode is convenient and simple, and the detection result is accurate and reliable.
Owner:杨旸

Engineered opsonin for pathogen detection and treatment

The present invention provides for engineered molecular opsonins that may be used to bind biological pathogens or identify subclasses or specific pathogen species for use in devices and systems for treatment and diagnosis of patients with infectious diseases, blood-borne infections or sepsis. An aspect of the invention provides for mannose-binding lectin (MBL), which is an abundant natural serum protein that is part of the innate immune system. The ability of this protein lectin to bind to surface molecules on virtually all classes of biopathogens (viruses, bacteria, fungi, protozoans) make engineered forms of MBL extremely useful in diagnosing and treating infectious diseases and sepsis.
Owner:PRESIDENT & FELLOWS OF HARVARD COLLEGE

Lymph targeted nuclear magnetic resonance imaging contrast agent with brown algal polysaccharide serving as carrier and preparation method and application of lymph targeted nuclear magnetic resonance imaging contrast agent with brown algal polysaccharide serving as carrier

The invention relates to contrast agents for medical science, in particular to a lymph targeted nuclear magnetic resonance imaging contrast agent with brown algal polysaccharide serving as a carrier and a preparation method and application of the lymph targeted nuclear magnetic resonance imaging contrast agent with the brown algal polysaccharide serving as the carrier. The macromolecular contrast agent high in water solubility is prepared by taking the brown algal polysaccharide as the carrier, taking mannose or mannose derivatives as a mannose receptor MBP (mannose binding protein) recognition group and taking paramagnetic metal ion chelates as a nuclear magnetic resonance imaging group. Lymph tissue binding force is increased, and combination of the mannose or mannose derivative group introduced into the synthetic contrast agent with mannose receptors enriched in lymph tissues is realized. In addition, after hypodermic injection of the contrast agent, lymph vessels and lymph glands are clearly developed under scanning of a nuclear magnetic resonance equipment, lymph gland signal enhancement rate of one side, with the contrast agent injected, of an animal body is remarkably increased while enhancement time is remarkably prolonged, distinct drawing and precise positioning of the lymph glands and the lymph vessels are realized, and a great significance to examination and diagnosis of lymphatic diseases is achieved.
Owner:OCEAN UNIV OF CHINA

Application of agglutinin II protein of rhizome of manyflower solmonaeal in pharmacy

InactiveCN1562351AStrong RPHI activityRPHI activity is obviousPeptide/protein ingredientsDigestive systemAntigenImmunodeficiency virus
An application of the polygonalectin II protein is preparing the medicine for preventing and reating hepatitis B and AIDS is disclosed as it can effectively suppress the HepG2.2.1.5 cell to secret antigens HBeAg and HBsAg, and the activity of HIV.
Owner:SICHUAN UNIV

Application of polygonatum cyrtonema Hua. Lectin II protein in medicine preparation for treating or preventing AIDS

Disclosed is Polygonatum cyrtonema Hua.Lectin II (PCL II), a plant protein isolated and purified from Siberian solomonseal rhizome, which has very strong inhibitory action to human immunodeficiency virus (HIV), thus can be used for preparing medicament for the prevention and treatment of AIDS.
Owner:SICHUAN UNIV

Method for early diagnosing acute kidney injury caused by contrast medium by utilizing MBL (mannan-binding lectin)

The invention relates to a method for early diagnosing an acute kidney injury caused by a contrast medium by utilizing urine MBL (mannan-binding lectin), which comprises the following steps of: comparing fluorescence difference electrophoresis charts of the urine of a patient 24 hours after an operation and the basis urine of the patient before the operation, and searching out a plurality of differentially expressed protein spots; identifying through a matrix-supported laser desorption ionization time of flight mass spectrometry technique to discover that the mannan-binding lectin (MBL) and serine protease related to the MBL are both increased in the differentially expressed protein spots, and the difference has a statistical significance for prompting that the acute kidney injury caused by the contrast medium is related to a pathway of MBL (mannan-binding lectin) complement activation, which is verified by a patient with the kidney injury caused by the contrast medium through an urine ELISA (enzyme-linked immuno sorbent assay) way. If applied to the clinic, the method of the invention can be used for detecting the urine MBL (mannan-binding lectin) 24 hours after an operation through the ELISA (enzyme-linked immuno sorbent assay) way and early diagnosing the kidney injury caused by the contrast medium, which is 24 hours earlier than the diagnosis of serum creatinine, and provides basis for early clinical diagnosis, early treatment and improvement of prognosis.
Owner:贾明宏

Methods and compositions for the regulation of lectin complement pathway (LCP)-associated complement activation in hyperglycemic myocardial damage

The present invention relates to methods and compositions for regulating lectin complement pathway (LCP)-associated complement activation. In particular, the invention relates to methods and compositions for inhibiting LCP-associated complement activation in order to inhibit hyperglycemic myocardial damage. The invention also relates to the treatment of cardiomyopathy and / or hypertrophy, such as cardiac hypertrophy. The invention also relates to methods and compositions for inhibiting the loss of cardiac progenitor cells by inhibiting LCP-associated complement activation. The methods include both in vitro and in vivo methods. The methods can be accomplished by contacting a mammalian cell having a surface exposed mannose binding lectin (MBL) ligand, such as a cardiac cell, with an effective amount of a MBL inhibitor to inhibit LCP-associated complement activation.
Owner:THE BRIGHAM & WOMEN S HOSPITAL INC

Method for inspecting infectious gene MBL related to SARS CoV infection and MBL infectious gene

The present invention relates to the PCR product sequencing assay of mannose-binding lectin gene (MBL) correlative with the susceptibility of SARS-CoV infection. The present invention also relates to the assay of the haplotypes correlative with the susceptibility of SARS-CoV infection that is composed of three single nucleotide polymorphism sites(SNPs): MBL gene G-550C,G-221C and G+230A. The said assay is to determine the genotype of the three SNPs by sequencing the PCR product first and then to calculate the haplotypes with PHASE programme. The present invention further relates to the detection kit of the above SNPs and the usage. Furthermore, the present invention combines the G+230A polymorphism sites and the haplotype composed of G-550C,G-221C and G+230 with SARS-CoV susceptibility, confirms that MBL is a new susceptibility gene included in SARS-CoV infection, and provides new genetic counseling content for the prevention and control of SARS-CoV infection of the population.
Owner:INST OF RADIATION MEDICINE ACAD OF MILITARY MEDICAL SCI OF THE PLA

Rapid detection method of TTK enzyme activity and application of rapid detection method

The invention relates to a rapid detection method of TTK enzyme activity and an application of the rapid detection method. The detection method includes 1), taking a to-be-detected sample, blank control and positive control to perform co-incubation with TTK enzyme and MBP / ATP (mannose-binding protein / adenosine triphosphate) mixture respectively to produce ADP (adenosine diphosphate); 2), respectively adding ADP-Glo<TM> reaction reagents to three groups of kinase reaction systems for co-incubation, and terminating the kinase reaction and consuming the remaining TAP; 3), respectively adding kinase detection reagents to the reaction systems for co-incubation to convert ADP to ATP, and reading the luminous value RLU of the newly synthesized ATP; 4), calculating the TTK enzyme activity according to the formula: the enzyme activity=(RLU(Sample)-RLU(Blank)) / (RLU(Pos.Ctrl)-RLU(Blank))X100%. On the basis of ADP-Glo<TM> kinase experiment, the reaction process is quantified by direct direction ofATP consumed in the reaction; the reaction is carried out in 384-hole plates, which does not involve repeated suction and washing process, the operation error is small, the flux is increased, and themethod is suitable for a large number of microhole plate operation combined with high-flux liquid transfer workstation equipment; the method is stable in system, high in precision and can be used forscreening TTK target inhibitors and TTK target related drugs.
Owner:武汉合研生物医药科技有限公司

Synthesis method of nanoparticle surface modifier

The invention provides a synthesis method of a nanoparticle surface modifier. A chemical synthesis method is utilized to combine water-soluble dithiodiols with mannitose to obtain dithiodiol mannitose derivatives. The products can be used for carrying out functionalization modification on Au, Ag, Cd and other metals and semiconductor material surfaces under the covalent combination action of the sulfhydryl group, and the bare mannitose structure on the other end can be specifically combined with canavaline (ConA). The mannitose derivative modified / silver nanoparticle process and the specific recognition process of ConA and mannitose can be characterized by obvious changes (generally red shift) of the SPR image color of the mono nanoparticles in real time under a dark field microscope (DFM). The saccharide-nanoparticles obtained by surface modification of the functional molecule are low in toxicity and stable in the solution, and have the advantages of favorable biocompatibility, favorable stability and efficient targeted recognition capability for trace canavaline.
Owner:NANJING UNIV OF POSTS & TELECOMM

Application of MBL in preparing drug for preventing or treating obesity and method for screening drug for preventing or treating obesity

The invention relates to application of MBL in preparing a drug for preventing or treating obesity and a method for screening the drug for preventing or treating the obesity, and belongs to the technical field of biotechnology and medicine. The MBL levels of normal control serum and obese patient serum are studied, and the MBL level of the obese patient serum is obviously less than the normal control serum. The gene editing technology is utilized to obtain mannose-binding lectin gene-deficient mice and find that MBL gene knockout significantly aggravates the blood glucose metabolism disorder in obese mice, and the fat cell volume is increased. An experiment of MBL inhibiting adipocyte differentiation shows that MBL can inhibit the adipocyte differentiation by down regulating the adipogenicdifferentiation related genes C / EBP alpha and PPAR gamma. From above, the MBL and the obesity have a close relationship. Therefore, the mannose-binding lectin can be used for preparing the drug for preventing or treating the obesity and preparing the drug for inhibiting the adipogenic differentiation of 3T3-L1 preadipocytes.
Owner:XINXIANG MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products